Dalbavancin / Oritavancin / Telavancin

What it's for

Dalbavancin, oritavancin, and telavancin are semi-synthetic lipoglycopeptide antibiotics related to the vancomycin family, grouped here as a skin/infection library entry. They treat selected serious gram-positive infections, including acute bacterial skin and skin-structure infections (ABSSSI (serious bacterial skin infections)), per each drug’s label.

What it does for the body

They treat selected serious gram-positive infections, including acute bacterial skin and skin-structure infections (ABSSSI (serious bacterial skin infections)), per each drug’s label. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

They bind the D-Ala-D-Ala terminus of peptidoglycan precursors, inhibiting cell-wall synthesis. Lipid tails improve anchoring and, for some agents, enable infrequent IV (into a vein) dosing. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Dalbavancin / Oritavancin / Telavancin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Skin research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Dalbavancin / Oritavancin / Telavancin — FDA.gov search
• ClinicalTrials.gov search: Dalbavancin / Oritavancin / Telavancin — U.S. clinical trials registry
• Drugs@FDA search: Dalbavancin / Oritavancin / Telavancin — FDA drug database (if approved)
• PubMed search: Dalbavancin / Oritavancin / Telavancin — NCBI PubMed
• PubMed Central search: Dalbavancin / Oritavancin / Telavancin — NCBI PMC

Reference

No ref on file.